Please use this identifier to cite or link to this item: https://hdl.handle.net/10356/87398
Title: Characterization of liposomal carriers for the trans-scleral transport of Ranibizumab
Authors: Joseph, Rini Rachel
Tan, Dulcia Wei Ni
Ramon, Moreno Raja Miguel
Natarajan, Jayaganesh V.
Agrawal, Rupesh
Wong, Tina TzeeLing
Venkatraman, Subramanian
Keywords: Liposomes
Ranibizumab
Issue Date: 2017
Source: Joseph, R. R., Tan, D. W. N., Ramon, M. R. M., Natarajan, J. V., Agrawal, R., Wong, T. T., et al. (2017). Characterization of liposomal carriers for the trans-scleral transport of Ranibizumab. Scientific Reports, 7(1), 16803-.
Series/Report no.: Scientific Reports
Abstract: Age-related macular degeneration (AMD) is a leading cause of blindness in the modern world. The standard treatment regimen for neovascular AMD is the monthly/bimonthly intravitreal injection of anti-VEGF agents such as ranibizumab or aflibercept. However, these repeated invasive injections can lead to sight-threatening complications. Sustained delivery by encapsulation of the drug in carriers is a way to reduce the frequency of these injections. Liposomes are biocompatible, non-toxic vesicular nanocarriers, which can be used to encapsulate therapeutic agents to provide sustained release. The protein encapsulation was performed by a modified dehydration-rehydration (DRV) method. The liposomes formed were characterized for size, zeta potential, encapsulation efficiency, stability, in vitro release, and ex vivo release profiles. In addition, the localization of the liposomes themselves was studied ex vivo. Entrapment-efficiency of ranibizumab into 100-nm liposomes varied from 14.7 to 57.0%. Negatively-charged liposomes prepared from DPPC-DPPG were found to have the slowest release with a low initial burst release compared to the rest of liposomal formulations. The ex vivo protein release was found to slower than the in vitro protein release for all samples. In conclusion, the DPPC-DPPG liposomes significantly improved the encapsulation and release profile of ranibizumab.
URI: https://hdl.handle.net/10356/87398
http://hdl.handle.net/10220/44429
ISSN: 2045-2322
DOI: http://dx.doi.org/10.1038/s41598-017-16791-7
Rights: © 2017 The Author(s) (Nature Publishing Group). This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. Te images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.
Fulltext Permission: open
Fulltext Availability: With Fulltext
Appears in Collections:MSE Journal Articles

Files in This Item:
File Description SizeFormat 
Characterization of liposomal carriers for the trans-scleral transport of Ranibizumab.pdf2.53 MBAdobe PDFThumbnail
View/Open

Google ScholarTM

Check

Altmetric

Items in DR-NTU are protected by copyright, with all rights reserved, unless otherwise indicated.